Stock Events

Stock Events

Enliven Therapeutics 

$59.32
976
-$0.33-0.55% Friday 19:59
+$0.00+0%Friday 20:01After hours

Statistics

Day High
59.89
Day Low
58.97
52W High
62.32
52W Low
14.79
Volume
1,113,059
Avg. Volume
1,420,760
Mkt Cap
4.35B
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

18NovExpected
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q1 2026
Q2 2026
Next
-0.57
-0.49
-0.4
-0.32
Expected EPS
-0.428925
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
0Revenue
-103.69MNet Income

Analyst Ratings

74.71Average Price Target
The highest estimate is 80.00.
From 8 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow ELVN. It's not an investment recommendation.
Microsoft
3
MSFT
Amazon
3
AMZN
NVIDIA
3
NVDA
Alphabet
3
GOOGL

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Merck
MRK
Mkt Cap366B
Merck & Co., Inc. is a global healthcare company that operates in the same oncology space, competing directly with Enliven Therapeutics' cancer-focused therapies.
Bristol-Myers Squibb
BMY
Mkt Cap136B
Bristol-Myers Squibb is involved in discovering, developing, and delivering innovative medicines in areas including oncology, directly competing with Enliven Therapeutics.
Pfizer
PFE
Mkt Cap159.36B
Pfizer Inc. has a broad range of oncology products that compete in the same market as Enliven Therapeutics' cancer treatments.
Astrazeneca
AZN
Mkt Cap252.33B
AstraZeneca PLC has a strong focus on oncology, with a portfolio that competes with Enliven Therapeutics in developing cancer therapies.
Novartis
NVS
Mkt Cap292.35B
Novartis AG focuses on innovative healthcare solutions, including oncology, where it competes with Enliven Therapeutics in the cancer treatment space.
Roche
RHHBY
Mkt Cap334.28B
Roche Holding AG, through its pharmaceuticals division, is a leader in oncology, directly competing with Enliven Therapeutics in cancer drug development.
Gilead Sciences
GILD
Mkt Cap180.64B
Gilead Sciences, Inc. is known for its strong presence in the oncology market, offering competitive therapies to those developed by Enliven Therapeutics.
AMGEN
AMGN
Mkt Cap233.78B
Amgen Inc. competes in the biopharmaceutical space, focusing on innovative therapies including oncology, which puts it in direct competition with Enliven Therapeutics.
Regeneron Pharmaceuticals
REGN
Mkt Cap81.77B
Regeneron Pharmaceuticals, Inc. is involved in the discovery and development of pharmaceutical products for the treatment of cancer, among other diseases, competing with Enliven Therapeutics.

Regions

About

Enliven Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics. The product candidates of the company include ELVN-001 is designed to specifically target the BCR-ABL fusion gene product, the oncogenic driver for patients with chronic myeloid leukemia (CML), ELVN-002 is designed to inhibit wild-type HER2 and key mutations of HER2.
Show more...
CEO
Richard A. Fair
Employees
67
Country
United States
ISIN
US29337E1029

Listings

BOATS
BOATS
ELVN.BOATS
XNAS
US
ELVN

0 Comments

Share your thoughts

FAQ

What is Enliven Therapeutics stock price today?▼
The current price of ELVN is $59.32 USD — it has decreased by -0.55% in the past 24 hours. Watch Enliven Therapeutics stock price performance more closely on the chart.
What is Enliven Therapeutics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on XNAS exchange Enliven Therapeutics stocks are traded under the ticker ELVN.
Is Enliven Therapeutics stock price growing?▼
ELVN stock has risen by +2.52% compared to the previous week, the month change is a -0.64% fall, over the last year Enliven Therapeutics has showed a +194.39% increase.
What is Enliven Therapeutics market cap?▼
Today Enliven Therapeutics has the market capitalization of 4.35B
When is the next Enliven Therapeutics earnings date?▼
Enliven Therapeutics is going to release the next earnings report on November 18, 2026.
What were Enliven Therapeutics earnings last quarter?▼
ELVN earnings for the last quarter are -0.49 USD per share, whereas the estimation was -0.39 USD resulting in a -26.56% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Enliven Therapeutics revenue for the last year?▼
Enliven Therapeutics revenue for the last year amounts to 0 USD.
What is Enliven Therapeutics net income for the last year?▼
ELVN net income for the last year is -103.69M USD.
How many employees does Enliven Therapeutics have?▼
As of September 05, 2026, the company has 67 employees.
In which sector is Enliven Therapeutics located?▼
Enliven Therapeutics operates in the Health & Wellness sector.
When did Enliven Therapeutics complete a stock split?▼
The last stock split for Enliven Therapeutics was on February 24, 2023 with a ratio of 1:4.
Where is Enliven Therapeutics headquartered?▼
Enliven Therapeutics is headquartered in BURLINGAME, United States.